Biomedicines · 2019 · 11 citations · 10 references
PharmacyBiochemistryPharmaceutical AnalysisBiopharmaceuticsGlycobiologyMolecular PharmacologyChromatographyLiquid ChromatographyReference Product ComparisonTest Product ComparisonAmino Acid AnalysisAmino Acid Composition AnalysisAnalytical Size-exclusion ChromatographyCation-exchange ChromatographyDrug Product ComparisonHigh-performance Size-exclusion ChromatographyMolecular Weight Distribution AnalysisSize-exclusion Liquid Chromatography
Herein we compared 40 mg/mL lots of the active ingredient, glatiramer acetate, manufactured by Mylan/Natco to the active ingredient, glatiramer acetate in Copaxone (Teva Pharmaceuticals, Ltd., Netanya Israel) using physicochemical (PCC) methods and biological assays. No differences were seen between the Mylan/Natco and Teva lots with some low resolution release PCC assays (amino acid analysis, molecular weight distribution, interaction with Coomassie Brilliant Blue G-250). Changes in polydispersity between Mylan/Natco and Copaxone lots were found using size exclusion chromatography and the high resolution PCC method, known as Viscotek, and suggestive of a disparity in the homogeneity of mixture, with a shift towards high molecular weight polypeptides. Using RPLC-2D MALLS, 5 out of 8 Mylan/Natco lots fell outside the Copaxone range, containing a high molecular weight and high hydrophobicity subpopulation of polypeptides not found in Copaxone lots. Cation exchange chromatography showed differences in the surface charge distribution between the Copaxone and Mylan/Natco lots. The Mylan/Natco lots were found to be within Copaxone specifications for the EAE model, monoclonal and polyclonal binding assays and the in vitro cytotoxicity assay, however higher IL-2 secretion was shown for three Mylan/Natco lots in a potency assay. These observations provide data to inform the ongoing scientific discussion about the comparability of glatiramer acetate in Copaxone and follow-on products.
10
Rina Aharoni, Başak Kayhan, Raya Eilam et al. · Proceedings of the National Academy of Sciences · 2003 · 232 citations · Full text
Rina Aharoni, Dvora Teitelbaum, Ruth Arnon et al. · Proceedings of the National Academy of Sciences · 1999 · 191 citations
Life Sciences, Immunology, Neurology +17
Catherine A. Fromen, Tojan B. Rahhal, Gregory R. Robbins et al. · Nanomedicine Nanotechnology Biology and Medicine · 2015 · 170 citations · Full text